Amendments of the Specification

Please replace the paragraph beginning at page 34, lines 9-15 with the following amended paragraph (deleted text appears struck through and inserted text appears underlined):

-- T-cells specific for one or more polypeptide may be prepared in vitro or in vivo, using standard methodologies available to those of skill in the art. For example, T-cells may be isolated from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood isolated from the cancer patient, using a commercially available cell separation system such as an electro-mechanical magnetic cell separation system of ISOLEX® (Nexell Therapeutics, Inc., Irvine, Calif.) or those described within U.S. Pat. Nos. 5,240,856 and 5,215,926 and PCT Patent Application Nos. WO 89/06280, WO 91/16116, and WO 92/07243. Each of these patents is incorporated herein by reference. --

Please replace the paragraph beginning at page 35, lines 20-24 with the following amended paragraph:

-- An exemplary combined immunotherapeutic composition provided herein comprises a PAP/GM-CSF fusion protein in combination with an anti-VEGF (vascular endothelial growth factor) monoclonal antibody. For example, a suitable anti-VEGF antibody is the ~~humanized murine monoclonal antibody Bevacizumab~~ recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human VEGF in in vitro and in vivo assay systems. The antibody contains human framework regions and the complementary-determining regions of a murine antibody that binds to VEGF (Bevacizumab, AVASTIN®; Genentech, San Francisco, Calif.) ~~that~~ and is known to be effective in inhibiting tumor angiogenesis. --